Saltar al contenido
Merck
  • HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.

HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.

Frontiers in pharmacology (2018-01-13)
Wen-Tsung Huang, Yu-Hsuan Tsai, Shang-Hung Chen, Ching-Wen Kuo, Yao-Lung Kuo, Kuo-Ting Lee, Wen-Chung Chen, Pei Chih Wu, Chun-Yu Chuang, Siao Muk Cheng, Chun-Hui Lin, Euphemia Yee Leung, Yung-Chieh Chang, Chun Hei Antonio Cheung
RESUMEN

Intrinsic or acquired resistance to hormone therapy is frequently reported in estrogen receptor positive (ER

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Seroalbúmina bovina, lyophilized powder, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
CelLytic M, Cell Lysis Reagent, Suitable for Mammalian cell lysis and protein solubilization.
Sigma-Aldrich
Anticuerpo anti-actina, clon C4, ascites fluid, clone C4, Chemicon®
Sigma-Aldrich
Anti-Sp1 Antibody, Upstate®, from rabbit
Sigma-Aldrich
MISSION® esiRNA, targeting human HDAC2
Sigma-Aldrich
Anti-ATG5 Antibody, clone 177.19, clone 177.19, from mouse